Payment overview · 2025
General Payments
$1,560.03
82 reported records · 24 companies
Healthcare provider profile · identity verified
Randall Brian Rigdon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MERRITT ISLAND, FL · NPI 1396791455
Verified facts
What the public records show
CMS Open Payments records show Randall Brian Rigdon, MD received $1,560.03 in general payments during 2025 across 82 reported records.
Amgen Inc. accounted for 12.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Creon, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta, Veozah.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $194.32 | 12.5% | 18 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $181.43 | 11.6% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $176.17 | 11.3% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $138.43 | 8.9% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $105.78 | 6.8% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $94.91 | 6.1% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.87 | 5.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.47 | 5.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.30 | 5.2% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.06 | 3.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $52.33 | 3.4% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $38.60 | 2.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.60 | 2.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.55 | 2.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $26.54 | 1.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.60 | 1.6% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $21.51 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.51 | 1.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.02 | 1.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.72 | 1.2% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $18.25 | 1.2% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $17.31 | 1.1% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.24 | 1.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.51 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,560.03 | 82 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $181.43 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $155.81 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $149.76 | 13 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $138.43 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $94.91 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $86.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $86.47 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $81.30 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $81.30 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $79.20 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $66.19 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.06 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $56.54 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $52.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.14 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.43 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.43 | 3 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $39.59 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $38.60 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $38.51 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $30.55 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.19 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 127 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 47 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 321 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 99 | exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
209 | 49 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
321 | 56 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
200 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1238 | 341 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1174 | 333 |
| Lisinopril | Lisinopril | 963 | 280 |
| Alprazolam | Alprazolam | 959 | 195 |
| Losartan Potassium | Losartan Potassium | 903 | 265 |
| Amlodipine Besylate | Amlodipine Besylate | 870 | 257 |
| Omeprazole | Omeprazole | 777 | 255 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 748 | 214 |
| Metformin Hcl | Metformin Hcl | 575 | 164 |
| Gabapentin | Gabapentin | 567 | 171 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 546 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 527 | 164 |
| Tamsulosin Hcl | Tamsulosin Hcl | 459 | 147 |
| Zolpidem Tartrate | Zolpidem Tartrate | 441 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 432 | 141 |
| Simvastatin | Simvastatin | 417 | 122 |
| Metoprolol Tartrate | Metoprolol Tartrate | 382 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 371 | 115 |
| Testosterone Cypionate | Testosterone Cypionate | 370 | 83 |
| Methylprednisolone | Methylprednisolone | 360 | 262 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 356 | 121 |
| Azithromycin | Azithromycin | 332 | 247 |
| Lorazepam | Lorazepam | 322 | 73 |
| Trazodone Hcl | Trazodone Hcl | 322 | 89 |
| Ozempic | Semaglutide | 321 | 56 |
| Tramadol Hcl | Tramadol Hcl | 296 | 84 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 283 | 53 |
| Montelukast Sodium | Montelukast Sodium | 277 | 80 |
| Furosemide | Furosemide | 272 | 95 |
| Meloxicam | Meloxicam | 270 | 92 |
| Oxycodone Hcl | Oxycodone Hcl | 269 | 35 |
| Temazepam | Temazepam | 258 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 234 | 70 |
| Allopurinol | Allopurinol | 233 | 64 |
| Sertraline Hcl | Sertraline Hcl | 233 | 68 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 227 | 77 |
| Carvedilol | Carvedilol | 213 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 212 | 76 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 210 | 150 |
| Farxiga | Dapagliflozin Propanediol | 209 | 49 |
| Prednisone | Prednisone | 208 | 99 |
| Duloxetine Hcl | Duloxetine Hcl | 202 | 60 |
| Eliquis | Apixaban | 200 | 55 |
| Ezetimibe | Ezetimibe | 193 | 72 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 178 | 135 |
| Pravastatin Sodium | Pravastatin Sodium | 175 | 55 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 173 | 49 |
| Potassium Chloride | Potassium Chloride | 167 | 53 |
| Clonazepam | Clonazepam | 157 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 45 |
| Finasteride | Finasteride | 149 | 45 |
| Progesterone | Progesterone, Micronized | 148 | 44 |
| Testosterone | Testosterone | 137 | 35 |
| Atenolol | Atenolol | 136 | 35 |
| Famotidine | Famotidine | 134 | 47 |
| Lovastatin | Lovastatin | 134 | 38 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 132 | 86 |
| Alendronate Sodium | Alendronate Sodium | 131 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 131 | 46 |
| Estradiol | Estradiol | 127 | 43 |
| Jardiance | Empagliflozin | 127 | 33 |
| Valacyclovir | Valacyclovir Hcl | 126 | 60 |
| Diazepam | Diazepam | 124 | 37 |
| Cephalexin | Cephalexin | 123 | 83 |
| Spironolactone | Spironolactone | 119 | 37 |
| Fluconazole | Fluconazole | 118 | 68 |
| Glimepiride | Glimepiride | 116 | 31 |
| Glipizide Er | Glipizide | 115 | 30 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 110 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 110 | 34 |
| Xarelto | Rivaroxaban | 109 | 32 |
| Synthroid | Levothyroxine Sodium | 108 | 27 |
| Liothyronine Sodium | Liothyronine Sodium | 106 | 30 |
| Glipizide | Glipizide | 100 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 99 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 98 | 65 |
| Ibuprofen | Ibuprofen | 97 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 26 |
| Chlorthalidone | Chlorthalidone | 93 | 27 |
| Bupropion Xl | Bupropion Hcl | 92 | 33 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 92 | 18 |
| Metformin Hcl Er | Metformin Hcl | 92 | 25 |
| Celecoxib | Celecoxib | 87 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 84 | 44 |
| Sumatriptan Succinate | Sumatriptan Succinate | 84 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 27 |
| Levofloxacin | Levofloxacin | 81 | 65 |
| Ondansetron Odt | Ondansetron | 81 | 42 |
| Fenofibrate | Fenofibrate | 77 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 23 |
| Mupirocin | Mupirocin | 75 | 52 |
| Fenofibrate | Fenofibrate Nanocrystallized | 74 | 24 |
| Methocarbamol | Methocarbamol | 74 | 30 |
| Morphine Sulfate Er | Morphine Sulfate | 74 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 73 | 24 |
| Benazepril Hcl | Benazepril Hcl | 72 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 20 |
| Nystatin | Nystatin | 68 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 20 |
| Buspirone Hcl | Buspirone Hcl | 66 | 25 |
| Mounjaro | Tirzepatide | 66 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 64 | 15 |
| Enalapril Maleate | Enalapril Maleate | 64 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 23 |
| Pregabalin | Pregabalin | 62 | 16 |
| Repatha Syringe | Evolocumab | 62 | 11 |
| Repatha Sureclick | Evolocumab | 60 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 56 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 13 |
| Januvia | Sitagliptin Phosphate | 53 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 52 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 34 |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Anastrozole | Anastrozole | 48 | 15 |
| Propranolol Hcl | Propranolol Hcl | 48 | 12 |
| Linzess | Linaclotide | 47 | 14 |
| Irbesartan | Irbesartan | 46 | 12 |
| Primidone | Primidone | 46 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 44 | 31 |
| Dutasteride | Dutasteride | 44 | 13 |
| Meclizine Hcl | Meclizine Hcl | 44 | 26 |
| Topiramate | Topiramate | 44 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 42 | 11 |
| Amoxicillin | Amoxicillin | 41 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 12 |
| Methotrexate | Methotrexate Sodium | 40 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 35 | 11 |
| Np Thyroid | Thyroid,pork | 35 | 11 |
| Acyclovir | Acyclovir | 34 | 11 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Metronidazole | Metronidazole | 33 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 33 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | 12 |
| Mometasone Furoate | Mometasone Furoate | 31 | 11 |
| Sucralfate | Sucralfate | 31 | 11 |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 19 |
| Rybelsus | Semaglutide | 30 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | 15 |
| Armour Thyroid | Thyroid,pork | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Naproxen | Naproxen | 27 | 12 |
| Nifedipine Er | Nifedipine | 27 | 12 |
| Nitroglycerin | Nitroglycerin | 27 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 24 | 14 |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | 16 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Baclofen | Baclofen | 20 | 11 |
| Bumetanide | Bumetanide | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Desloratadine | Desloratadine | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 18 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 18 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Praluent Pen | Alirocumab | 17 | suppressed |
| Trandolapril | Trandolapril | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Veozah | Fezolinetant | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 15 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | 13 |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Triazolam | Triazolam | 15 | suppressed |
| Xyosted | Testosterone Enanthate | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Enbrel Sureclick | Etanercept | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Meperidine Hcl | Meperidine Hcl | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,560.03 · 82 records | Amgen Inc. | AIRSUPRA, AREXVY, AVEIR, CAPLYTA, CREON, Cologuard Collection Kit, FANAPT, FREESTYLE LIBRE 3, JARDIANCE, JATENZO, KRYSTEXXA, Korlym, LEQVIO, LINZESS, MOUNJARO, NEFFY, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TERIPARATIDE, TRELEGY ELLIPTA, Tlando, UBRELVY, UNITHROID, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN FLX, XIFAXAN, ZAVZPRET, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error